Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of PBI-4050 on the Pharmacokinetics of Midazolam, a Sensitive Cytochrome P450 3A Substrate, in Healthy Adult Subjects
Sponsor: Celerion
Listed as NCT03637049, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Celerion, it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE1
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celerion
- Liminal BioSciences Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .